Insider buying last 90 days
No open-market insider purchases were filed for MEDP in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Medpace's week centers on record Q3 2026 results, with revenue of $716 million up 8.5% year over year, EBITDA of $172.1 million rising 16%, and net income up 23.7% to $137.5 million. EPS came in at $4.84 against an estimate of $4.44, and the company posted all-time-high net new business awards of $873 million for the quarter, with last-12-month awards up 23.9% to $3.02 billion. The board also authorized a new $1 billion share repurchase program, and coverage this week has debated whether the stock is now fully valued following the beat and record backlog. A general counsel stock sale was also disclosed in a Form 4 filing during the period.
The stock closed at $672.93, up 3% on the day, and sits above both its 50-day average of $623.99 and its 200-day average of $530.79, with the 50-day above the 200-day. The GekkoIndex reads 54.2, placing it in the Neutral zone. Price stands 21.5% above Gekko Fair Value of $554.06, a sizable premium to that benchmark.
The next earnings date falls on 8 February 2027, outside a typical 20-day holding window. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows. Seasonally, the next 20 trading days have averaged a 3.6% decline over 5 years, with gains in only 1 of them, a pattern worth noting given the stock's recent run toward its 52-week high of $693.97.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Medpace scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
Above 50 and 200-day
Close $653.94 is above the 50-day ($629.52) and 200-day ($532.01) averages, and the 50-day is above the 200-day.
See the chart57, Neutral
Reading 57 is in the Neutral zone.
See the GekkoIndex19.7% above
Price is 19.7% above Gekko Fair Value (more than 5% above).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 85 days
Next report Feb 8, 2027, 85 days away — outside a typical 20-trading-day hold.
See earnings−2.9% on average
From this point in the calendar, the next 20 trading days averaged −2.9% over 5 years, rising in 1 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Medpace closed at $653.94 on Nov 13, 2026, +9.4% over the past year, inside a 52-week range of $373.00 to $693.97.
Use the left and right arrow keys to read daily values.
Put MEDP on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Medpace provides contract research services that support the clinical development of new medical products. It works with pharmaceutical, biotechnology, and medical device companies, guiding studies from early Phase I testing through to post-market Phase IV surveillance. The company is recognized for covering this full span of drug and device development under one roof.
Its work spans designing trial programs, running central laboratory operations, managing projects and regulatory filings, overseeing clinical trials, and handling data management and pharmacovigilance. Medpace also assists clients with new drug application submissions and continued clinical monitoring after products reach the market. Beyond these core services, it operates bio-analytical laboratories, conducts human pharmacology studies, and offers imaging and ECG reading services used in clinical research. Its client base extends across North America, Europe, and Asia.
Medpace was founded in Cincinnati, Ohio, in 1992, where it remains based. Its shares are listed on the NASDAQ under the ticker MEDP.
Medpace’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 57, in the Neutral zone, up 0.9 points over five sessions.
Up 0.9 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 28 | −0.1% | +1.0% | ||
| Accumulation | 176 | +1.8% | +2.3% | ||
| Neutral (current zone) | 440 | +0.6% | +2.7% | ||
| Distribution | 51 | −0.8% | +8.3% | ||
| Selling | 7 | Too few readings yet | |||
Average MEDP share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Medpace trades 19.7% above Gekko Fair Value of $546.25, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Medpace shares are worth, recalculated every trading day.
$546.25
Gekko Fair Value, Nov 14, 2026
19.7% Overvalued
At the end of Aug 2026 the price was 15.6% above the estimate.
No open-market insider purchases were filed for Medpace, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for MEDP in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in MEDP were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Medpace has been buying back its own shares.
From company filings.
1of the funds Gekko tracks holds MEDP.
Medpace reports on Feb 8, 2027 (85 days away), and beat the EPS estimate in 8 of its last 8 reports.
Feb 8, 2027
85 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 21, 2026 | $4.84 est $4.44 | $716.0M est $714.5M | +5.1% |
| Jul 22, 2026 | $4.25 est $3.98 | $707.3M est $689.5M | +13.9% |
| Apr 22, 2026 | $4.28 est $3.96 | $706.6M est $697.6M | −23.6% |
| Feb 9, 2026 | $4.67 est $4.19 | $708.5M est $689.3M | −17.7% |
| Oct 22, 2025 | $3.86 est $3.53 | $659.9M est $641.0M | +9.3% |
| Jul 21, 2025 | $3.10 est $2.98 | $603.3M est $538.8M | +53.2% |
| Apr 21, 2025 | $3.67 est $3.06 | $558.6M est $526.3M | −4.7% |
| Feb 10, 2025 | $3.68 est $3.12 | $536.6M est $539.7M | −7.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Medpace is $651.31, −0.4% from the last close, from 9 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 9 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 26 | BMO Capital | $670 | +2.5% |
| Oct 23 | UBS | $700 | +7.0% |
| Oct 23 | Barclays | $675 | +3.2% |
| Oct 23 | TD Cowen | $673 | +2.9% |
| Oct 23 | Robert W. Baird | $699 | +6.9% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Medpace averaged −2.9% across the last 5 years, rising in 1 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −2.4% | 2 of 5 |
| Next 10 trading days | −4.4% | 0 of 5 |
| Next 15 trading days | −4.8% | 0 of 5 |
| Next 20 trading days | −2.9% | 1 of 5 |
| Next 30 trading days | −0.8% | 2 of 5 |
For scale, MEDP’s typical 20-trading-day move in either direction is about 7%.
Medpace’s market cap is $18.29B, with a P/E ratio of 35.9 and revenue of $2.84B over the last twelve months.
Coverage of Medpace this week reads neutral: 2 positive, 4 neutral and 0 negative headlines.
Medpace’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| SHOPShopify | Accumulation | 0.6% above |
| CTASCintas | Neutral | 22.3% above |
| PYPLPayPal | Neutral | 5.3% above |
| XYZBlock | Neutral | 15.1% above |
| FISVFiserv | Distribution | 38.0% below |
| CPAYCorpay | Distribution | 5.1% below |
A peer links to its own page where one exists.
Medpace’s market cap is $18.29B at the Nov 13, 2026 close of $653.94, with 27.97M shares outstanding. The shares trade on a P/E ratio of 35.9.
The consensus analyst 12-month price target for Medpace is $651.31, −0.4% from the last close. Of the 9 firms that rated the stock in the last 90 days, 3 rate it a buy, 6 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Medpace is overvalued: the Nov 13, 2026 close of $653.94 is 19.7% above Gekko Fair Value of $546.25. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Medpace is expected to report on Feb 8, 2027 (85 days away). Analysts expect earnings of $4.82 per share on revenue of $718.4M. Medpace beat the earnings estimate in 8 of its last 8 reports, moving 16.9% on average across the report.
Medpace’s 52-week high is $693.97 and its 52-week low is $373.00; it closed at $653.94 on Nov 13, 2026, +9.4% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 1 as mixed (gekkoindex) and 2 as headwinds (fair value and seasonality). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.